Napp impresses NICE with Levact evidence
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has today recommended Napp's chemotherapy drug Levact (bendamustine) for treating patients with chronic lymphocytic leukaemia. The institute was so impressed with the strength of the evidence supporting the product that it jumped Levact straight to the final stages of guidance development.